A secondary methodological analysis of CCTG CO17 clinical trial Wednesday, June 26, 2019 A secondary methodological analysis. Advantages of the net benefit regression framework for trial-based economic evaluations of cancer treatments: an example from the Canadian Cancer Trials Group CO.17 trial Economic evaluations commonly accompany trials of new treatments or interventions; however, regression methods and their corresponding advantages for the analysis of cost-effectiveness data are not widely appreciated. This study looked to illustrate regression-based economic evaluation, by a review a cost-effectiveness analysis conducted by the Canadian Cancer Trials Group’s Committee on Economic Analysis and implement net benefit regression. The Results: Net benefit regression offers a simple option for cost-effectiveness analyses of person-level data. By placing economic evaluation in a regression framework, regression-based techniques can facilitate the analysis and provide simple solutions to commonly encountered challenges (e.g., the need to adjust for potential confounders, identify key patient subgroups, and/or summarize “challenging” findings, like when a more effective regimen has the potential to be cost-saving). You can read the article online: https://bmccancer.biomedcentral.com/articles/10.1186/s12885-019-5779-x Also special thanks to The Canadian Centre for Applied Research in Cancer Control (ARCC) partnered with CCTG on this study. Citation Hoch JS, Hay A, Isaranuwatchai W, Thavorn K, Leighl NB, Tu D, Trenaman L, Dewa CS, O'Callaghan C, Pater J, Jonker D, Chen BE, Mittmann N. Advantages of the net benefit regression framework for trial-based economic evaluations of cancer treatments: an example from the Canadian Cancer Trials Group CO.17 trial (ONLINE). BMC Cancer 19: 552, 2019.
